Jubilant Pharmova has appointed Daniel J. O'Connor as the Chief Executive Officer (CEO) of its step-down subsidiary, Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company focused on oncology and autoimmune diseases.

O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors.

Most recently, he served as the CEO of Ambrx Biopharma, where he significantly increased the company's valuation, leading to its successful acquisition. His career also includes key leadership positions at ImClone Systems, Advaxis, and OncoSec Medical.

He holds a law degree from Penn State University's Dickinson School of Law and a B.A. from Boston University; he is also a former Captain in the U.S. Marine Corps.

Commenting on the occasion, Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman, Jubilant Pharmova Limited, said, "We are delighted to welcome Dan as we advance our mission of building a clinical-stage therapeutics company focused on developing innovative therapies across multiple cancer indications."